Biocon has received a Notice of Compliance from Health Canada for Bosaya and Vevzuo, both biosimilars referencing Prolia and Xgeva, respectively.

GlobalData analysts forecast a blockbuster future for Idvynso, though they note it is unlikely it will displace market dominator, Biktarvy.

Ray's MSD and Novo Holdings-backed Series B will shed light on the potential of the company's vision restoration gene therapy pipeline.

The treatment landscape for locally advanced head and neck squamous cell carcinoma (LA HNSCC) has changed significantly.

Lilly now has a lentiviral and LNP-based platform for in vivo delivery under its belt, which could broaden the company's chance of success.

MSD has received the EC approval for Enflonsia, indicated to prevent RSV lower respiratory tract disease in newborns and infants during their initial RSV season.

UCB has signed a definitive agreement to acquire Neurona Therapeutics in a deal worth up to $1.15bn, adding the latter’s lead asset NRTX-1001 to its epilepsy portfolio.

As in vivo cell therapies enter clinical trials, suppliers tackle the technical and logistical barriers to commercial viability.

The new site will focus on the use of AI models for purposes including the discovery and development of targeted medicines for patients with unmet medical needs.

CDMOs use of digital twins to realise a strategic advantage, Physical AI's rise in pharma manufacturing, and more.

Trump's executive order sets out to speed up the review of psychedelics, while supporting research into this burgeoning field.

Non-GLP-1 obesity drugs are emerging in the market, with this landscape expected to surge 50-fold, generating $15.5bn in 2031.